Armata Pharmaceuticals, Inc.ARMPNYSE
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank64
3Y CAGR-0.1%
Studio
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
-0.1%/yr
vs +32.8%/yr prior
Acceleration
-33.0pp
Decelerating
Percentile
P64
Within normal range
vs 3Y Ago
1x
Modest growth
Streak
1 yr
Consecutive declineElevated
PeriodValueYoY Change
202435.59-28.0%
202349.40+255.7%
202213.89-61.1%
202135.72-44.0%
202063.79-
20190.00-
20180.00-100.0%
201711.47+615.1%
2016-2.23-108.7%
201525.61-